Skip to main content
Delfa

← Trials/Trial dossier/NCT00099216

CompletedPhase 3

Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia

Asset

Rivastigmine

Listed sites

63

Recruiting sites

-

Enrollment

708

actual

Study population

Vascular cognitive impairment / dementia

Key I/E criterion

•Study partner/caregiver required

Primary endpoints

•Cognition•Global clinical impression of change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDCENA713BIA05
NCT IDNCT00099216

Timeline

Milestones

Study start2001-08 (month precision)
Study first posted2004-12-10estimated
Primary completion2005-11actual (month precision)
Study completion2005-11actual (month precision)
Last update posted2011-11-17estimated

Assets

Drug assets

Rivastigmine

Study populations

Who this study enrolls

Vascular cognitive impairment / dementia

Eligibility

Who can enroll

Minimum age50 Years
Maximum age85 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Between the ages of 50 and 85 years old
•Have contact with a responsible caregiver 3 or more days per week
•Be male or a female who is surgically sterilized or one year post menopausal

Exclusion criteria

•Current diagnosis of severe or unstable cardiovascular or other diseases
•Current diagnosis of active, uncontrolled seizure disorder, Parkinson's disease or Alzheimer's disease

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
4
Function / daily living
1

Function / daily living

1 endpoint
Secondary/protocol endpoint

Change in activities of daily living from baseline at week 24

change from baseline, improvement

Other (unclassified)

4 endpoints
Primary/protocol endpoint/low confidence

Change in cognition from baseline at week 24

change from baseline, improvement

Primary/protocol endpoint/low confidence

Global clinical impression of change from baseline at week 24

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in behavioral symptoms from baseline at week 24

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in clinical staging from baseline at week 24

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.